Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. [electronic resource]
Producer: 20090324Description: 292-302 p. digitalISSN:- 1535-7163
- Antibodies -- pharmacology
- Antibodies, Monoclonal -- pharmacology
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Boronic Acids -- pharmacology
- Bortezomib
- Carcinoma, Non-Small-Cell Lung -- enzymology
- Caspases -- metabolism
- Cell Death -- drug effects
- Cell Line, Tumor
- Death Domain Receptor Signaling Adaptor Proteins -- metabolism
- Drug Resistance, Neoplasm -- drug effects
- Drug Screening Assays, Antitumor
- Drug Synergism
- Enzyme Activation -- drug effects
- Humans
- Lung Neoplasms -- enzymology
- Pyrazines -- pharmacology
- Receptors, TNF-Related Apoptosis-Inducing Ligand -- immunology
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.